To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1. Planned registration period 2 years 2. Planned surveillance period for 4 years from 6 months after launch
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Adverse Events (AEs)
Timeframe: Up to approximately 12 months
General Improvement Rating
Timeframe: Approximately 1 year from administration
General health assessment on VAS
Timeframe: Approximately 1 year from administration
Changes in physician general assessment
Timeframe: Approximately 1 year from administration
Percentage of patients with Dermatology Life Quality Index (DLQI)
Timeframe: Approximately 1 year from administration
Change from baseline activity for arthritis
Timeframe: Approximately 1 year from administration